A continuing need for biostatistical collaboration throughout the institution and in all stages of clinical and translational research, including planning, design, conduct and data management, intermit and final analysis and reporting. The Biostatistical Resource Group (BRG) provides this consultation and collaboration for clinical investigators and basic scientists who hold National Cancer Institute funded grants or support from other approved peer-reviewed funding agencies. The staff from the BRG, in conjunction with the Clinical Trials Support Resource, participate in the review of a large number of clinical protocols that are developed at the M.D. Anderson Cancer Center or through cooperative groups and pharmaceutical corporation collaboration. From January 1, 1996 through December 31, 1996, 225 protocols were reviewed including 36 Phase I, 71 Phase II, 25 Phase III, 1 Phase IV, 12 Pilot, and 80 other studies. This number is expected to increase by 10 to 15% yearly. The Biostatistical Resource Group provides training in the area of biostatistical principles and methods for the design and analysis of studies. In conjunction with staff from the Division of Medicine, statistical and design issue pertinent to Phase I-III clinical trials have been incorporated into the training program. The BRG also develops a modest amount of biostatistical software for the design, monitoring and analysis of trials in which they are involved. The Biostatistics Resource Group is housed within the Department of Biomathematics in the Houston Main Building. In this environment, they are supported by the latest workstations, servers, and laser printers and the modern statistical and database management software packages.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-23
Application #
6268945
Study Section
Project Start
1998-09-04
Project End
1999-06-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
23
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ma, Grace X; Lee, Minsun M; Tan, Yin et al. (2018) Efficacy of a community-based participatory and multilevel intervention to enhance hepatitis B virus screening and vaccination in underserved Korean Americans. Cancer 124:973-982
Peng, Guang; Mills, Gordon B (2018) Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1. Clin Cancer Res 24:508-510
Radovich, Milan; Pickering, Curtis R; Felau, Ina et al. (2018) The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 33:244-258.e10
Tetzlaff, Michael T; Nelson, Kelly C; Diab, Adi et al. (2018) Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer 6:14
Tayob, Nabihah; Richardson, Peter; White, Donna L et al. (2018) Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol 18:1
Caruso, Joseph A; Duong, Mylinh T; Carey, Jason P W et al. (2018) Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res 78:5481-5491
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6

Showing the most recent 10 out of 12418 publications